Cargando…
Short- and Long-Term Antidepressant Clinical Trials for Major Depressive Disorder in Youth: Findings and Concerns
The diagnosis of major depressive disorder (MDD) in U.S. youth is increasing as is the rate of antidepressant medication (ADM) treatment for the disorder. Fluoxetine and escitalopram are FDA approved for the short term and maintenance treatment of MDD in youth. Placebo-controlled short-term ADM tria...
Autores principales: | Safer, Daniel J., Zito, Julie Magno |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6797591/ https://www.ncbi.nlm.nih.gov/pubmed/31681028 http://dx.doi.org/10.3389/fpsyt.2019.00705 |
Ejemplares similares
-
Antidepressant Use in Medicaid-Insured Youth: Trends, Covariates, and Future Research Needs
por: Zito, Julie M., et al.
Publicado: (2020) -
Potential of Antithrombin III as a Biomarker of Antidepressive Effect in Major Depressive Disorder
por: Song, Ruize, et al.
Publicado: (2021) -
Analysis of the Deleterious Single-Nucleotide Polymorphisms Associated With Antidepressant Efficacy in Major Depressive Disorder
por: Xin, Juncai, et al.
Publicado: (2020) -
Association Between Antidepressant Efficacy and Interactions of Three Core Depression-Related Brain Networks in Major Depressive Disorder
por: Wang, Qiang, et al.
Publicado: (2022) -
Antidepressant Treatment-Induced State-Dependent Reconfiguration of Emotion Regulation Networks in Major Depressive Disorder
por: Zhao, Lei, et al.
Publicado: (2022)